Evaluation of a standardized protocol using lepirudin or argatroban for heparin-induced thrombocytopenia
Pre-post protocol study published in Cardiovascular & Hematological Agents in Medicinal Chemistry (2011)
Abstract
STUDY OBJECTIVE: To evaluate the effectiveness of our institutions heparin-induced thrombocytopenia (HIT) protocol in achieving a therapeutic activated partial thromboplastin time (aPTT) and to evaluate patient outcomes related to bleeding and thrombotic events before and after protocol implementation. DESIGN: Retrospective, single-center, pre- and post- assessment of a protocol previously approved at our institution. SETTING: 400-bed community hospital serving surrounding rural populations with emphasis in cardiothoracic surgery. PATIENTS: Retrospective chart review based on drug charge data identified 29 patients that received either argatroban or lepirudin for greater than 24 hours. Nineteen patients received either argatroban or lepirudin prior to HIT-protocol implementation, while the remaining ten received either drug after the HIT protocol was implemented. INTERVENTION: Implementation of HIT protocol occurred in March 2009. Patients were divided into pre-protocol and post-protocol groups. RESULTS: Primary outcome was to evaluate the number of therapeutic, subtherapeutic, and supratherapeutic aPTTs between two groups. In the pre-protocol group, aPTTs were therapeutic, subtherapeutic, and supratherapeutic 48.5% (164/338), 14.2% (48/338), and 37.2% (126/338) of the time, respectively. Meanwhile aPTTs in the post-protocol group were therapeutic, subtherapeutic, and supratherapeutic 46.6% (89/191), 22% (42/191), and 31.4% (60/191) of the time, respectively. The number of subtherapeutic aPTTs was statistically higher in the post-protocol group compared to the pre-protocol group. Secondary endpoints included the number of bleeding events and number of thrombotic events. None of the secondary endpoints reached statistical significance. Time to therapeutic aPTT was also evaluated: in the pre-protocol group median time (range) was 15 hours (2-108.6) compared to 8.1 hours (2.3-94.2) in the post-protocol group. CONCLUSIONS: Adoption and implementation of HIT protocol at our institution resulted in significantly more subtherapeutic aPTTs as compared to time prior to protocol. Although not statistically significant, the time required to obtain therapeutic aPTT was reduced by almost 50% after protocol implementation, which could be of clinical importance. Larger studies are needed to continue to assess if standardized protocols are effective in treatment of HIT.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Retrospective pre-post evaluation in 29 HIT patients showed that a standardized lepirudin/argatroban protocol shortened time-to-therapeutic-aPTT by ~50% (15 → 8.1 h median) but had more subtherapeutic aPTTs than pre-protocol practice.
Warum dies für die Hirudotherapie relevant ist
Diese retrospektive, monozentrische Prä- und Post-Implementierungsstudie evaluierte ein standardisiertes institutionelles HIT-Protokoll mit Lepirudin oder Argatroban bei 29 Patienten und bewertete das Erreichen der therapeutischen aktivierten partiellen Thromboplastinzeit (aPTT) sowie Blutungskomplikationen und thrombotische Ereignisse. Der Abstract berichtet, dass subtherapeutische aPTT-Werte post-Protokoll statistisch signifikant häufiger auftraten, während sekundäre Endpunkte (Blutungen, thrombotische Ereignisse) keine Signifikanz erreichten; die Zeit bis zum Erreichen der therapeutischen aPTT wurde um nahezu die Hälfte reduziert, allerdings ohne statistische Signifikanz. Die Relevanz des Artikels für ASHs Fachgebiet ist begrenzt: Lepirudin wird nur als eines von zwei Medikamenten im Protokoll genannt, und der Abstract liefert keine Informationen, die es mit Egeln, Hirudin-Biologie oder egelsderivativer Therapie verknüpfen. EINSCHRÄNKUNG: Es handelt sich um eine kleine retrospektive Prä/Post-Bewertung an einem einzigen 400-Bett-Krankenhaus mit nur 10 Post-Protokoll-Patienten; die Ergebnisse werden nicht nach Medikament aufgeschlüsselt, und der Abstract enthält keinerlei Inhalte zur Hirudotherapie oder zum Egelsekretom.
Zitation
Evaluation of a standardized protocol using lepirudin or argatroban for heparin-induced thrombocytopenia.
Kennedy K et al. · Cardiovascular & Hematological Agents in Medicinal Chemistry, 2011
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026